Class / Patent application number | Description | Number of patent applications / Date published |
514120000 | C=O other than as ketone or aldehyde, attached directly or indirectly to phosphorus | 80 |
20080214507 | MONO-AND-DI-PHOSPHATES OF 3-(3-FLUORO-4-HYDROXY-PHENYL)-7-HYDROXY-NAPHTHALENE-1-CARBONITRILE - Compounds of formula II | 09-04-2008 |
20080242640 | Surfactant Lipids, Compositions Thereof and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 10-02-2008 |
20080318908 | USE OF GABA AND GABAB AGONISTS - The present invention provides methods of stimulating tissue growth, including islet cell growth, by administering GABA or a GABA agonist to act on GABA | 12-25-2008 |
20090029949 | GPCR Ligands Identified by Computational Modeling - Disclosed are pharmacophores for developing and screening compounds having G-protein-coupled receptor antagonist activity, including LPA | 01-29-2009 |
20090029950 | Composition for Reducing the Exudation of Serum Proteins - Disclosed is a composition for reducing the exudation of the serum proteins. More specifically the composition of the present invention relates to a composition capable of improving conditions such as atopic dermatitis, atopic eczema, skin pruritus, atopic nasitis, atopic erythema or erythroderma, contact dermatitis, asthma, chronic obstructive pulmonary disease, etc. by reducing the exudation of the serum proteins in skin and mucosa. | 01-29-2009 |
20090075946 | NOVEL TRITERPENIC ACID DERIVATIVE AND PREPARATION FOR EXTERNAL APPLICATION FOR SKIN COMPRISING THE SAME - In a triterpenic acid having hydroxyl groups, at least one of the hydroxyl groups is phosphorylated to produce a phosphorylated triterpenic acid and/or a salt thereof, thereby improving the solubility of the triterpenic acid in a preparation for external application for the skin and allowing the physiological activity of the triterpenic acid to be exerted satisfactorily. The phosphorylated triterpenic acid is preferably, for example, ursolic acid phosphate and/or a salt thereof. The preparation for external application for the skin is preferably a cosmetic, particularly preferably a quasi-drug. | 03-19-2009 |
20090137532 | Aldolase-inhibiting aromatic compounds - The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two carbon atoms adjacent to the same aromatic chain, i.e., the first aromatic chain, and R is a phosphate group or a phosphate group mimetic linked to a carbon atom of the second aromatic chain. | 05-28-2009 |
20090306019 | Compositions for treatment of eosinophilia and related disorders - The present invention discloses compositions comprising phosphatidic acid and uses thereof for the treatment of subjects suffering from eosinophilia or related disorders such as asthma and/or the prevention of these disorders in subjects having environmental or genetic predisposition thereto. | 12-10-2009 |
20100056485 | NANOSOAP CONTAINING SILVER NANOPARTICLES - Disclosed herein is a silver nanoparticle based antimicrobial composition and methods for making the same. The antimicrobial composition comprises an amphiphilic molecule having at least one hydrophilic group and at least hydrophobic groups attached thereto; and an at least one silver nanoparticle in contact with the amphiphilic molecule. Also disclosed are uses for the antimicrobial composition such as for the treatment of skin disorders. | 03-04-2010 |
20100113398 | Treatment and/or Prevention of Non-Viral Epithelial Damage - There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic acid, or a pharmaceutically acceptable derivative of such an acid. There are also provided methods of treatment using such inhibitors, acids and derivatives. | 05-06-2010 |
20100160261 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF - There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | 06-24-2010 |
20100298274 | FAT CONTAINING COMPOSITION - A composition comprises a fat phase wherein the fat phase comprises: more than 10 wt. % DHA and/or EPA or derivatives thereof; or more than 5 wt. % GLA or a derivative thereof; or more than 10 wt. % of GLA, EPA and/or DHA in total or derivatives thereof; and secoisolariciresinol (SECO) or a derivative thereof, with the proviso that when the composition comprises GLA, the composition is substantially free of isoflavones. The composition and mixtures or blends comprising the composition may be used for the treatment of PMS and prostate conditions. | 11-25-2010 |
20110015160 | METHODS OF TREATING NEUROLOGICAL DISEASES USING DOCOSAHEXAENOIC ACID AND ARACHIDONIC ACID COMPOSITIONS - A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels. | 01-20-2011 |
20110021465 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from Krill oil, in which said krill oil contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 01-27-2011 |
20110086820 | ANALGESIC AGENT COMPRISING CYCLIC PHOSPHATIDIC ACID DERIVATIVE - An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid. | 04-14-2011 |
20110098253 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use - The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. | 04-28-2011 |
20110105438 | Oligomer-Foscarnet Conjugates - The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds. | 05-05-2011 |
20110105439 | Ceramide Production Promoter - Provided are a drug, a cosmetic, etc. for promoting production of ceramide. | 05-05-2011 |
20110118213 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS - This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: | 05-19-2011 |
20110124607 | COMPOSITION FOR REGULATION CELLULAR SENESCENCE COMPRISING LYSOPHOSPHATIDIC ACID AND INHIBITOR OF ADENYLYL CYCLASE AS ACTIVE INGREDIENTS - The present invention relates to the molecular mechanism inducing cell proliferation in aged human fibroblasts by inhibiting AMPK using LPA and AC inhibitor. Particularly, the present invention relates to a composition comprising LPA and ACI as active ingredients and the invention proves with the said composition that LPA and ACI regulate different phosphorylation of AMPKα and thus inactivate p53 and induce senescent cell proliferation. This results support the fact that AMPK signal transduction plays an important role in cell proliferation of senescent cells. | 05-26-2011 |
20110218177 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS - The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient. | 09-08-2011 |
20110230448 | Treatment and/or Prevention of Non-Viral Epithelial Damage - There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic acid, or a pharmaceutically acceptable derivative of such an acid. There are also provided methods of treatment using such inhibitors, acids and derivatives. | 09-22-2011 |
20110275600 | METHODS FOR INCREASING ENDOGENOUS PLASMALOGEN LEVELS - The invention provides methods for increasing endogenous plasmalogen levels in an animal by administering to the animal an endogenous plasmalogen level increasing amount of one or more long chain polyunsaturated fatty acids (LCPUFAs). | 11-10-2011 |
20120083472 | PHARMACEUTICAL COMPOSITION FOR PROMOTING THE HEALING OF WOUNDS AND CONTAINING LYSOPHOSPHATIDIC ACID AND AN ADENYLYL CYCLASE INHIBITOR AS ACTIVE INGREDIENTS - The present invention relates to a pharmaceutical composition for promoting the healing of wounds, containing lysophosphatidic acid and an adenylyl cyclase inhibitor as active ingredients, and more particularly, to a pharmaceutical composition which contains an adenylyl cyclase inhibitor and which promotes the healing of wounds in senescent cells or aged persons having physiological characteristics different than those of young cells or young persons. In addition, the present invention relates to a method for promoting the healing of wounds involving treating a wounded person with an effective dose of the lysophosphatidic acid and adenylyl cyclase inhibitor. | 04-05-2012 |
20120220553 | THE USE OF LPA FOR ENCOURAGING PREGNANCY, AND FERTILITY AGENT - The objective is to find compounds which have an activity to improve the success rate of pregnancy and implantation in blastocyst transfer in mammals, to provide a method of producing and using the compounds, and to provide a pregnancy-promoting agent. Disclosed is a pregnancy-promoting agent containing one or more lysophosphatidic acids selected from the group consisting of LPA-C16:0, LPA-C16:1, LPA-C18:0, LPA-C18:1 and LPA-C18:2. | 08-30-2012 |
20120225849 | 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition - A prodrug of 2-methoxyestradiol (2-ME | 09-06-2012 |
20130005691 | ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS - The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens. | 01-03-2013 |
20130005692 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from Krill oil, in which said krill oil contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 01-03-2013 |
20130085120 | Phosphate Ester Compound of Hydroxy Acid Substituted Phenol Ester, Preparation Method and Medical Use Thereof - Phosphate ester compound of hydroxy acid substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), in which Y=C | 04-04-2013 |
20130225533 | DOCOSAHEXAENOIC ACID BOUND IN PHOSPHOLIPIDS AND METHOD OF RECOVERING SAME FROM A NATURAL SOURCE - Medicaments and therapeutic compositions contain (1) phospholipids having 4,7,10,13,16,19-docosahexaenoic acid covalently bound thereto and (2) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, wherein about 25% of the total 4,7,10,13,16,19-docosahexaenoic acid moieties in the composition are covalently bound to phospholipids, and wherein components (1) and (2) are present in amounts effective to support overall neurological health in a subject. | 08-29-2013 |
20130244984 | Ceramide Production Promoter - Provided are a drug, a cosmetic, etc. for promoting production of ceramide. | 09-19-2013 |
20130281410 | METHODS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS - The invention provides methods for the treatment of major depressive disorder in male subjects and methods for the treatment of psychiatric disorders at high altitudes by administering one or more creatine-containing compounds. | 10-24-2013 |
20130338113 | MATERIALS AND METHODS FOR TREATING VIRAL INFECTIONS - The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus). | 12-19-2013 |
20140080791 | OMEGA-3 PHOSPHOLIPID SUPPLEMENTS FOR FEMALES - The invention relates to omega-3 phospholipid supplements for females, and in particular to omega-3 phospholipid supplements with increased bioavailability as evidenced by increased EPA and DHA in plasma phospholipids and an increase in omega-3 index as compared to males. In preferred embodiments, the omega-3 phospholipid is krill oil. | 03-20-2014 |
20140088047 | USE OF LONG CHAIN POLYUNSATURATED FATTY ACID DERIVATIVES TO TREAT SICKLE CELL DISEASE - The present invention relates to the use of long chain polyunsaturated fatty acids to treat diseases associated with red blood cells and cell membranes, and in particular to the use of derivatives of long chain fatty acids to treat sickle cell disease. | 03-27-2014 |
20140274968 | OMEGA-3 PHOSPHOLIPID SUPPLEMENTS FOR IMPROVED BRAIN MATURITY - The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil. | 09-18-2014 |
20140329775 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE - Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions. | 11-06-2014 |
20150087621 | COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE - Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt. | 03-26-2015 |
20150306051 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine. | 10-29-2015 |
20150352132 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE - It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided. | 12-10-2015 |
20160024125 | NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS - Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non-β-oxidizable fatty acids. | 01-28-2016 |
20160128967 | PROCESS AND COMPOSITION FOR STABILIZATION OF VULNERABLE PLAQUE UTILIZING A COMBINATION OF A STATIN AND OMEGA 3 FATTY ACIDS - A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition, the compositions and method designed to stabilize vulnerable plaque while mediating omega-3 deficiencies in individuals in need thereof. | 05-12-2016 |
20160158180 | Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments - Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state. | 06-09-2016 |
20160158181 | Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments - Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state. | 06-09-2016 |
514121000 | Plural C=O groups, other than as ketone or aldehyde | 32 |
20080234232 | Methods and compositions for targeting AFAP - Embodiments of the invention are directed to methods and compositions for inhibiting activation of cSrc by human actin filament associated protein (AFAP). Libraries and methods of screening compositions for inhibitive activity are also provided. Also provided are methods of treating cancer. Cancer may be, for example, but is not limited to ovarian cancer, breast cancer, and gastrointestinal cancer. Also provided are methods of decreasing resistance to chemotherapy. | 09-25-2008 |
20090048215 | Compositions for Ameliorating a Reduced Higher Brain Function Resulting From Organic Brain Lesions - A composition that has an activity of ameliorating reduced higher brain functions resulting from organic brain lesions, said composition comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid as well as docosahexaenoic acid and/or a compound having docosahexaenoic acid as a constituent fatty acid. | 02-19-2009 |
20090170816 | COMBINATION COMPRISING SQUALENE, A PHOSPHOLIPID AND AN OMEGA 3 FATTY ACID FOR THE TREATMENT OF CANCER - Pharmaceutical composition which comprises squalene or its pharmaceutically acceptable derivatives; at least one phospholipid, its salts or pharmaceutically acceptable derivatives; and at least one omega-3 fatty acid, its salts or pharmaceutically acceptable derivatives. Use of the composition in the preparation of a drug designed for the prophylaxis, treatment and/or improvement of cancer symptoms in mammals. The invention also relates to a fodder for animals such as dogs and cats which comprises the composition. | 07-02-2009 |
20090197839 | Method of obtaining total fixed lipids from seeds of the sapodilla family, for the preparation of cosmetics and dermatological pharmaceutical compositions - Procedure for the obtaining a concentrate of the total fixed lipids of the kernels of the family Sapotaceae, genus | 08-06-2009 |
20090306020 | Combination therapy comprising diaryl ureas for treating diseases - The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound and an PI3K/AKT signaling pathway inhibitor. Useful combinations include e.g. BAY-43-9006 as a diaryl urea compound. | 12-10-2009 |
20100035843 | METHODS FOR ATTENUATING ALLERGEN-INDUCED AIRWAY HYPERREACTIVITY USING CD1D DEPENDENT ANTAGONISTS - The present invention is directed to a method of inhibiting allergen-induced airway CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Methods of the invention are useful for treatment and prevention of air-way hyperactivity caused by an allergen, and results in the attenuation of CD1d-restricted immune responses, including treatment of hay fever and asthma are due to air-way hyperactivity, and for systemic administration to attenuate ongoing immune responses. Preferably, these compositions are in a form intended for administration via nasal passages or directly inhaled to the air-ways. | 02-11-2010 |
20100063006 | COMPOSITIONS AND METHODS TO REDUCE FAT AND RETRACT SKIN - Compositions, methods, and apparatuses for treatment of subcutaneous fat tissue for the purpose of fat tissue reduction or other alterations of the subcutaneous fat tissue which affect the appearance of the overlying skin layer. | 03-11-2010 |
20100137258 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention relates to thiophosphi(o)nic acid derivatives having formula (I) wherein. M is a [C(R | 06-03-2010 |
20100279985 | LIVER FUNCTION-PROTECTING AGENT - Disclosed is a liver function-protecting agent which comprises a phospholipid as an active ingredient, and which can exhibit an excellent prophylactic and ameliorating effect on the deterioration in the liver function when ingested orally. Also disclosed is a liver function-protecting food, beverage or feed. The phospholipid is preferably one derived from milk or a milk material. Alternatively, the phospholipid may be used in the form of a phospholipid-containing composition prepared from milk or a milk material and containing the phospholipid in an amount of 10 wt % or more relative to the total solid content. | 11-04-2010 |
20100311696 | TOPICAL SKIN TREATMENT COMPOSITION - The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin. The present invention further relates to the topical application to the skin of such compositions, and/or preparations containing them, for the prevention and/or treatment of damage to skin. | 12-09-2010 |
20110065673 | NOVEL LEUKOTRIENE RECEPTOR AGONIST - It is an object of the present invention to provide a leukotriene receptor antagonist that can be conveniently prepared from a natural source. | 03-17-2011 |
20110077224 | LINOLEIC PHOSPHOLIPIDS AND USES THEREOF FOR INHIBITING INFLAMMATORY AND NEURODEGENERATIVE PROCESSES - Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment. | 03-31-2011 |
20110098254 | COMPOSITIONS COMPRISING PHOSPHOLIPIDS - The present invention provides compositions comprising phospholipids and particularly those comprising at least 40% phospholipid and at least 80% phospholipid as a percentage of total fat in the extract, comprising polyunsaturated and saturated phospholipids, in a ratio of saturated phospholipid to monounsaturated to polyunsaturated phospholipid of about 6:3:1 respectively, or comprising at least 40% phospholipid and less than 40% protein and methods for their production from dairy products. | 04-28-2011 |
20120277196 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 11-01-2012 |
20130079310 | STATIN AND OMEGA 3 FATTY ACIDS FOR REDUCTION OF APOLIPOPROTEIN-B LEVELS - A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. | 03-28-2013 |
20130217654 | Surfactant Lipids, Compositions Thereof, and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 08-22-2013 |
20130338114 | COMPOSITIONS FOR INCREASING STRENGTH, MUSCLE MASS, AND LEAN BODY MASS - Phosphatidic acid, lyso-phosphatidic acid, and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachectic patients, as well as resistance training individuals, to improve nitrogen balance. The oral administration of phosphatidic acid as well as other actives described herein was found to increase muscle hypertrophy, strength, and lean body mass, and to decrease body fat in subjects, for example, when combined with resistance training. | 12-19-2013 |
20140107080 | BRAIN FUNCTION IMPROVING AGENT - Brain function improving agents, cognitive judgment ability improving agents, as well as foods and beverages that contain krill oil as an active ingredient are provided. | 04-17-2014 |
20140323442 | Small Molecule Modulators of pRb Inactivation - The present invention provides a small molecule treatment of diseases/conditions caused by a virus carrying a viral oncoprotein. In one embodiment, the virus which carries the viral oncoprotein is HPV. The small molecule useful herein includes thiadiazolin-3,5-dione compounds having an optionally substituted aryl group bound to one nitrogen atom of said thiadiazolin-3,5-dione compound. The small molecules may also be administered with a compound which inhibits binding of HPV E6 to p53. In one embodiment, the thiadiazolin-3,5-dione compound has formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R | 10-30-2014 |
20140364399 | PHOSPHOLIPID COMPOSITIONS ENRICHED FOR PALMITOLEIC, MYRISTOLEIC OR LAUROLEIC ACID, THEIR PREPARATION AND THEIR USE IN TREATING METABOLIC AND CARDIOVASCULAR DISEASE - The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R | 12-11-2014 |
20140364400 | ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS - The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens. | 12-11-2014 |
20150038469 | COMPOSITIONS FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins. | 02-05-2015 |
20150119368 | CHOLESTEROL ABSORPTION INHIBITOR AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF CHOLESTEROL AND FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR, CARDIAC AND VASCULAR EVENTS - A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. | 04-30-2015 |
20150299103 | PRODRUGS OF MONOMETHYL FUMARATE (MMF) - The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis. | 10-22-2015 |
20150376162 | NSAIDs DERIVATIVES AND USES THEREOF - The present invention discloses novel compounds derived from NSAIDs and pharmaceutically acceptable salts thereof. Other aspects of the invention relate to use of the NSAID derivatives in treating inflammatory diseases and pharmaceutical compositions thereof. | 12-31-2015 |
20160120888 | ANTICANCER DRUG - An anti-cancer agent and a cancer cell death inducing agent, containing an inositol phospholipid compound, particularly 1,2-O-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycerol-3-phosphatidyl-inositol, as an active ingredient. | 05-05-2016 |
20160175366 | ENHANCED OMEGA-3 FORMULATIONS | 06-23-2016 |
20170232013 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES | 08-17-2017 |
514122000 | Malathion | 4 |
20080269174 | Fungicidal Combinations - A formulated mixture useful for treating plant propagation material comprising (A) Tebuconazole; and (B) one or more compounds selected from Carboxin, Chlorothalonil, Difenoconazole, Azoxystrobin, Fluquinconazole, Metalaxyl, Mefenoxam, Thiram, Abamectin, Lambda-cyhalothrin, Beta-cyflutrin, Tefluthrin, Thiamethoxam, Flubendamide and a compound of formula (A-1) and (C) one or more customary formulation adjuvants; with the proviso that the mixture excludes the mixtures consisting, as active ingredients, of (I) tebuconazole, carboxin and tridimenol and (II) tebuconazole, difenconazole and fludioxonil. | 10-30-2008 |
20110269718 | PHARMACEUTICAL COMPOSITION CONTAINING MALATHION AND VOLATILE CYCLIC SILICONE - The invention described comprises using volatile silicone oils in stabilising malathion. The invention also comprises pediculicidal and/or nit-killing compositions comprising malathion and volatile silicone oils and also excipients for topical use. | 11-03-2011 |
20120010175 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE - The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes. | 01-12-2012 |
20120172338 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF - The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present topical formulations encompass a non-flammable solvent for malathion effective in killing head lice. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same. | 07-05-2012 |
514124000 | C=O, other than as ketone or aldehyde, attached to a benzene ring | 4 |
20090318393 | Film-forming liquid formulations for controlled release of pesticides - A controlled pesticide delivery system includes a film-forming alkanol solution of at least one amphiphilic polymer and at least one pesticide composition for the treatment of at least one pest in gardens, landscapes, forests, and wooden structures, targeting at least one pest selected from fire ants, tent caterpillars, gypsy moths, wood-boring beetles, and bark beetles during at least one phase of their life cycles. | 12-24-2009 |
20100069336 | HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 03-18-2010 |
20150031651 | PRODRUGS OF VITAMINE K - The invention relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma. | 01-29-2015 |
20160184254 | COMPOSITIONS COMPRISING VITAMIN K DERIVATIVES AND SALTS - This application relates to new formulations of vitamin K1 and K2 provitamins. These formulations can be used as nutraceuticals, e.g. for the fortification of foods or simply in supplements or can be used in pharmaceuticals for the treatment of a variety of conditions known to benefit from the administration of vitamin K1 and K2. | 06-30-2016 |